Activate your own defense

Latest news

26.11.2019

MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million

MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.

The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.

PDF: English Français

More news

About MaxiVAX

The first company with an encapsulated cellular cancer immunotherapy

MaxiVAX is a Swiss clinical-stage biotechnology company which, having completed a first-in-man Phase I clinical study, is now planning to perform several Phase II multicenter studies in different types of cancer.

Learn more

Cancer Immunotherapy

A paradigm-shift in cancer treatment

First generation cancer immunotherapies are paving the way for MaxiVAX’s personalized immunotherapy.

Learn more

Product  

MVX-ONCO-1

A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer.

Learn more

Team

Highly experienced product development team

A very seasoned team with extensive experience in the fields of clinical oncology, cell therapy, quality assurance, clinical research and regulatory affairs.

Learn more

Contact info

Do you need more information? Feel free to contact us

MaxiVAX
Rue de l'Athénée 24
1206 Geneva
Switzerland

+41 22 552 26 13